Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis

Song,Peng; Yin,Qin; Lu,Ming; Fu,Bo; Wang,Baolin; Zhao,Qinghong

doi:10.3892/etm.2015.2284

Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis

Authors:
- Peng Song
- Qin Yin
- Ming Lu
- Bo Fu
- Baolin Wang
- Qinghong Zhao
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China, Medical Center of Pediatrics, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China
Published online on: February 11, 2015 https://doi.org/10.3892/etm.2015.2284
Pages: 1393-1400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognostic impact of excision repair cross‑complementation group 1 (ERCC1) expression in gastric cancer (GC) has been investigated for decades, but has yielded controversial results. The aim of the present study was to provide a precise evaluation of whether the expression levels of ERCC1 are associated with overall survival (OS) in patients with GC. A systematic search of Medline and Embase was conducted. Original studies concerning OS and ERCC1 expression were included for critical appraisal. A total of 15 studies comprising 1,425 patients with GC were identified. The results revealed that high/positive ERCC1 expression was an indicator of poor survival in patients with GC [hazard ratio (HR) 1.48; 95% confidence interval (CI) 1.02‑2.10; P=0.036; I2=83.8%; random‑effects model] compared with low/negative ERCC1 expression. Subgroup analysis indicated that high/positive ERCC1 expression had a significant unfavorable impact on OS in the group of patients evaluated by reverse transcription polymerase chain reaction (RT‑PCR; HR 2.57; 95% CI 1.49‑4.45). Furthermore, high/positive ERCC1 expression was found to be associated with poor survival in patients receiving platinum‑based chemotherapy in the RT‑PCR group (HR 2.13; 95% CI 1.06‑4.27). These data suggest that ERCC1 may be a useful prognostic factor for GC. In addition, low mRNA levels of ERCC1 appear to be associated with a significant favorable OS benefit from platinum‑based chemotherapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol. 11:837–843. 2000. View Article : Google Scholar : PubMed/NCBI
3	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
4	Sijbers AM, de Laat WL, Ariza RR, et al: Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 86:811–822. 1996. View Article : Google Scholar : PubMed/NCBI
5	Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chen WW, Wang F and Xu RH: Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One. 8:e689742013. View Article : Google Scholar : PubMed/NCBI
7	Richards D, McCollum D, Wilfong L, et al: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 19:104–108. 2008. View Article : Google Scholar
8	Yamada Y, Boku N, Nishina T, et al: Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 24:2560–2565. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wei J, Zou Z, Qian X, et al: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008. View Article : Google Scholar : PubMed/NCBI
10	Matsubara J, Nishina T, Yamada Y, et al: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 98:832–839. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
12	de Graeff P, Crijns AP, de Jong S, et al: Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 101:149–159. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
14	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
15	Baek SK, Kim SY, Lee JJ, Kim YW, Yoon HJ and Cho KS: Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat. 38:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
16	Bamias A, Karina M, Papakostas P, et al: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 65:1009–1021. 2010. View Article : Google Scholar : PubMed/NCBI
17	De Dosso S, Zanellato E, Nucifora M, et al: ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 72:159–165. 2013. View Article : Google Scholar : PubMed/NCBI
18	Fareed KR, Al-Attar A, Soomro IN, et al: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 102:1600–1607. 2010. View Article : Google Scholar : PubMed/NCBI
19	Huang ZH, Hua D, Du X, et al: ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol. 14:6401–6407. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kim JS, Kim MA, Kim TM, et al: Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 100:732–738. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kim KH, Kwon HC, Oh SY, et al: Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers. 16:74–82. 2011. View Article : Google Scholar
22	Kwon HC, Roh MS, Oh SY, et al: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 18:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
23	Liu YP, Ling Y, Qi QF, et al: The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett. 5:935–942. 2013.PubMed/NCBI
24	Ozkan M, Akbudak IH, Deniz K, et al: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev. 11:181–185. 2010.PubMed/NCBI
25	Qi YJ, Cui S, Yang YZ, et al: Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population. J Cancer Res Ther. 9:410–415. 2013. View Article : Google Scholar : PubMed/NCBI
26	Squires MH III, Fisher SB, Fisher KE, et al: Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer. 119:3242–3250. 2013. View Article : Google Scholar : PubMed/NCBI
27	Chen S, Zhang J, Wang R, Luo X and Chen H: The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 70:63–70. 2010. View Article : Google Scholar : PubMed/NCBI
28	Li S, Wu J, Chen Y, et al: ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis. Anticancer Drugs. 25:106–114. 2014. View Article : Google Scholar
29	Huang MY, Tsai HL, Lin CH, et al: Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol. 108:457–464. 2013. View Article : Google Scholar : PubMed/NCBI
30	Gerhard R, Carvalho A, Carneiro V, et al: Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 209:331–336. 2013. View Article : Google Scholar : PubMed/NCBI
31	Yin M, Yan J, Martinez-Balibrea E, et al: ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
32	Parker RJ, Eastman A, Bostick-Bruton F and Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 87:772–777. 1991. View Article : Google Scholar : PubMed/NCBI
33	Satoh A, Toyota M, Itoh F, et al: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63:8606–8613. 2003.PubMed/NCBI
34	Chen HY, Shao CJ, Chen FR, Kwan AL and Chen ZP: Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer. 126:1944–1954. 2010.